Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.46 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319421 | 0.84 | ADAMTS4 (0.48) | MEP1BITGAVPGRALDH1A1LMNA | |
| SCHEMBL4620884 | 0.82 | ADAMTS4 (0.55) | MEP1BITGAVPGRFFAR4KEAP1 | |
| SCHEMBL4620675 | 0.82 | ADAMTS4 (0.55) | MEP1BITGAVPGRFFAR4KEAP1 | |
| SCHEMBL4619809 | 0.82 | ADAMTS4 (0.55) | MEP1BITGAVPGRFFAR4KEAP1 | |
| SCHEMBL4328361 | 0.82 | MEP1B (0.47) | MEP1BITGAVPGRALDH1A1LMNA | |
| SCHEMBL4328353 | 0.82 | MEP1B (0.47) | MEP1BITGAVPGRALDH1A1LMNA | |
| SCHEMBL4620040 | 0.79 | ITGAV (0.62) | MEP1BITGAVPGRFFAR4KEAP1 | |
| SCHEMBL4621094 | 0.79 | ITGAV (0.62) | MEP1BITGAVPGRFFAR4KEAP1 | |
| SCHEMBL4621800 | 0.79 | ITGAV (0.62) | MEP1BITGAVPGRFFAR4KEAP1 | |
| SCHEMBL7354064 | 0.78 | MMP9 (0.69) | MEP1BPGRADAMTS4MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001838-B1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2597083-A2 | Selective hydroxamate based MMP inhibitors | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2597083-A2 | Selective hydroxamate based MMP inhibitors | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8314148-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314148-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2001838-A2 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117981-A2 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117981-A2 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | MMP13, MMP11, MMP14 | MEP1B 1259/4885ITGAV 3890/4885PGR 2458/4885 |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | MMP13, MMP11, MMP14 | MEP1B 1259/4885ITGAV 3890/4885PGR 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.